Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (6): 336-339.
Previous Articles Next Articles
FU Yi-jiao, WU Zhi-ang*
Received:
2014-01-06
Revised:
2016-02-03
Online:
2014-06-08
Published:
2016-03-02
CLC Number:
FU Yi-jiao, WU Zhi-ang. Drug Quality Problem Analysis Based on KMRW Model[J]. Chinese Journal of Pharmacovigilance, 2014, 11(6): 336-339.
Add to citation manager EndNote|Ris|BibTeX
[1] 郭其友,张晖萍.2001年诺贝尔经济学奖得主-乔治·阿克洛夫经济学思想述评[J].外国经济与管理,2001,23(11):44-48. [2] Darby M R, Karni E. Free competition and the optimal amount of fraud[J]. Journal of law and economics,1973,16(1):67-88. [3] Andersen E S. The evolution of credence goods: A transaction approach to product specification and quality control[M]. Aalborg Univers-itetsforlag,1994:21-25. [4] 经济之灵.经济学视野里的信用:一个文献综述[EB/OL].(2013-11-16)[2014-01-01]. http://web.cenet.org.cn/web/economysoul/index.php3?detail=2&file=detail.php3&id=30962. [5] 皮天雷.国外声誉理论:文献综述,研究展望及对中国的启示[J].首都经济贸易大学学报, 2009,11(3):95-96. [6] Morrison A D, Wilhelm W J. Partnership firms, reputation, and human capital[J].The American Economic Review, 2004, 94(5):1682-1692. [7] 晏国祥.企业声誉测评指标体系[M].北京:经济科学出版社,2009:22-41. [8] 张萍,赵佳.声誉传播:公务员道德风险控制的新选择[J].贵州社会科学,2011,(8):67-68. [9] 高晓鸥,宋敏,刘丽军.基于质量声誉模型的乳品质量安全问题分析[J].中国畜牧杂志,2010,46(10): 32-33. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||